Efficacy and Safety Profile of Different Schedules of Adjuvant Trastuzumab Therapy among Patients with HER2-Positive Breast Cancer: Real-World Experience from a Tertiary Cancer Center in South India

One year of adjuvant trastuzumab is the standard of care for HER2-positive breast cancer. In low–middle income countries, delivery of 1-year trastuzumab is challenging due to significant financial burden. Evidence for shorter durations of adjuvant trastuzumab is gaining popularity in this regard. In...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Nandini Devi Rajan, Abhilash Menon, Praveen Kumar Shenoy, Manuprasad Avaronnan, Sherin Shahana, Bindu Therayangalath
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	Thieme Medical and Scientific Publishers Pvt. Ltd. 2025-01-01
سلاسل:	South Asian Journal of Cancer
الموضوعات:	HER2-positive breast cancer adjuvant trastuzumab shorter durations of adjuvant trastuzumab
الوصول للمادة أونلاين:	http://www.thieme-connect.de/DOI/DOI?10.1055/s-0044-1791969
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!